- Conditions
- Non-Hodgkins Lymphoma
- Interventions
- Rituximab
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 2
- States / cities
- Kansas City, Kansas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–36
of 12
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hodgkin's Disease
- Interventions
- Nivolumab, Brentuximab vedotin
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 20
- States / cities
- Duarte, California • Long Beach, California • Los Angeles, California + 16 more
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- Rituximab (RTX), Tafasitamab, Bendamustine (BEN)
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 453 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 18
- States / cities
- Anaheim, California • Bakersfield, California • Burbank, California + 15 more
- Conditions
- Leukemia, Lymphoma, Graft Versus Host Disease
- Interventions
- cyclosporine, cyclosporine and methotrexate
- Drug
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2003
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Jacksonville, Florida • Atlanta, Georgia + 9 more
- Conditions
- Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
- Interventions
- Azacitidine, Durvalumab
- Drug · Biological
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 12
- States / cities
- New Haven, Connecticut • Washington D.C., District of Columbia • Gainesville, Florida + 9 more
- Conditions
- Diffuse Large B-cell Lymphoma, de Novo DLBCL, DLBCL Transformed From Indolent Lymphoma, Follicular Grade 3 Lymphoma
- Interventions
- Pixantrone + Rituximab, Gemcitabine + Rituximab
- Drug
- Lead sponsor
- CTI BioPharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 51
- States / cities
- Tucson, Arizona • Bentonville, Arkansas • Fayetteville, Arkansas + 39 more
- Conditions
- Multiple Myeloma
- Interventions
- Bortezomib, Isatuximab, Cyclophosphamide, Dexamethasone
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Multiple Myeloma
- Interventions
- Isatuximab, Iberdomide, Bortezomib (B), Dexamethasone, Melphalan, Linvoseltamab, On Body Delivery System (OBDS)
- Drug · Device
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 720 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2038
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Acute Myeloid Leukemia
- Interventions
- oral azacitidine (CC-486)
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Acalabrutinib, Bortezomib, Cyclophosphamide, Cytarabine, Doxorubicin Hydrochloride, Prednisone, Rituximab, Rituximab and Hyaluronidase Human
- Drug · Biological
- Lead sponsor
- Academic and Community Cancer Research United
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 3
- States / cities
- New York, New York • Charlotte, North Carolina • Seattle, Washington
- Conditions
- Myeloma
- Interventions
- Panobinostat, Bortezomib, Lenalidomide, Dexamethasone, Symptom Questionnaire
- Drug · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Plasma Cell Myeloma
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Daratumumab, Lenalidomide
- Procedure · Biological · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida